Abstract | PURPOSE: The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. EXPERIMENTAL DESIGN: A total of 13 patients entered the study. Three received irinotecan at 20 mg/m(2)/day (dose level I), 6 at 25 mg/m(2)/day (dose level II), and 4 at 22.5 mg/m(2)/day (dose level III). In 8 patients, plasma levels of irinotecan and its metabolites SN-38 and SN-38 glucuronide (SN-38glu) were measured by high-performance liquid chromatography and main pharmacokinetic parameters, including steady-state concentration, area under the time-concentration curve, and clearance, were calculated and normalized to the dose level of 22.5 mg/m(2)/day. RESULTS: Dose-limiting toxicity was grade 3-4 diarrhea, which occurred in 4 of 6 patients at dose level II and in 2 of 4 patients at dose level III. Therefore, we defined 22.5 mg/m(2)/day the maximum-tolerable dose and 20.0 mg/m(2)/day the recommended dose for Phase II studies. Hematological toxicity was rare. The pharmacokinetic data provided evidence that continuous infusion increased the metabolism of irinotecan to SN-38 with respect to standard 30/90-min administration. Indeed, the steady-state concentration of irinotecan, SN-38, and SN-38glu were 42.7 +/- 25.2, 14.9 +/- 1.9, and 31.7 +/- 3.5 nmol/liter, respectively, and the area under the time-concentration curves of irinotecan, SN-38, and SN-38glu were 6.94 +/- 0.41, 1.92 +/- 0.30, and 4.23 +/- 0.52 hx micro mol/liter, respectively. Twelve patients were evaluable for activity, and we observed 3 (25%) partial responses, 2 (17%) minor responses, and 4 (33%) disease stabilizations. CONCLUSIONS: The administration of irinotecan as a 7-day continuous infusion every 21 days is feasible with diarrhea being the dose-limiting toxicity; recommended dose for Phase II studies is 20.0 mg/m(2)/day. The comparison of the present data with those obtained after a standard 30-90 min. i.v. infusion of irinotecan demonstrates that continuous infusion improves the transformation of irinotecan to SN-38 and also results in increased glucuronidation of the active metabolite. Antitumor activity in pretreated metastatic colorectal cancer patients is encouraging.
|
Authors | Gianluca Masi, Alfredo Falcone, Antonello Di Paolo, Giacomo Allegrini, Romano Danesi, Cecilia Barbara, Samanta Cupini, Mario Del Tacca |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 10
Issue 5
Pg. 1657-63
(Mar 01 2004)
ISSN: 1078-0432 [Print] United States |
PMID | 15014016
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- 7-ethyl-10-hydroxycamptothecin glucuronide
- Antimetabolites, Antineoplastic
- Antineoplastic Agents, Phytogenic
- Glucuronides
- Quinazolines
- Thiophenes
- Irinotecan
- raltitrexed
- Fluorouracil
- Camptothecin
|
Topics |
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(administration & dosage, pharmacokinetics, toxicity)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use, toxicity)
- Camptothecin
(administration & dosage, analogs & derivatives, pharmacokinetics, therapeutic use, toxicity)
- Colorectal Neoplasms
(drug therapy, pathology)
- Diarrhea
(chemically induced)
- Female
- Fluorouracil
(therapeutic use)
- Glucuronides
(therapeutic use)
- Humans
- Infusions, Intravenous
- Irinotecan
- Male
- Middle Aged
- Nausea
(chemically induced)
- Neoplasm Metastasis
- Patient Selection
- Quinazolines
(therapeutic use)
- Thiophenes
(therapeutic use)
- Vomiting
(chemically induced)
|